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Inhibition of intestinal alpha glucosidase plays a major role in preventing rise in postprandial glucose level in diabetics.
Cymbopogon martinii (CM) (family Poaceae) is used in traditional Indian medicine in treatment of diabetes mellitus. The alpha
glucosidase inhibitory action of the plant is studied. The active component was separated using hot water extraction of the
whole plant powder, diﬀerential solvent extraction, and silica gel column chromatography. The 30:70 toluene : ethyl acetate
fraction showed optimum activity. The silica gel chromatography fraction demonstrated 98, 98, and 68% inhibition for starch,
maltose, and sucrose, respectively, at 5mg/kg body weight of rats. Intestinal absorption studies using noneverted intestinal sacs,
as well as in vivo studies in streptozotocin-induced diabetic rats using oral glucose tolerance with maltose and sucrose load,
revealed better inhibition of alpha glucosidase as compared to acarbose. Kinetic studies using Lineweaver Burk plot showed mixed
to noncompetitive type of inhibition by CM. In vivo studies with maltose load of 2mg and 3mg/gm body weight showed a
noncompetitive pattern of inhibition at 5mg/kg body weight of CM as against 60mg/kg body weight of acarbose. Thus CM is
more eﬀective alpha glucosidase inhibitor and at lower concentration than acarbose.
1.Introduction
Diabetes mellitus is a progressive metabolic disorder of glu-
cose metabolism that eventually leads to micro- and macro-
vascular changes causing secondary complications that are
diﬃcult to manage [1]. The control of hyperglycemia is
therefore of prime importance to halt the progression of the
disease. While use of insulin, secretagogues, and sensitizers
constitutes the predominant line of therapy, use of inhibitors
of intestinal absorption of sugar is vital as they do not
interfere with the sugar metabolism and help control hyper-
glycemiainanoninvasivemanner.Thealphaglucosidasesare
exoglycosidases found on the luminal surface of enterocytes
containing maltase/glucoamylase and sucrase/isomaltase
activity [2]. Alpha glucosidase inhibitor, acarbose, is shown
to control postprandial hyperglycemic shoot up [3] and is
safe and well tolerated [4]. Alpha glucosidase inhibitors are
useful as they reduce the cardiovascular risk [1].
Cymbopogon martinii (CM) also known as Rosha Grass
is mainly used in perfume industry. The plant is used
traditionally in treatment of diabetes. The plant has also
been documented in Ayurveda for treatment of urinary
tract infection, as anti-inﬂammatory and as diuretic [5]. In
the present study Cymbopogon martinii (CM) belonging to
the poaceae (Gramineae) family has been evaluated for its
antidiabetic action through inhibition of alpha glucosidase
in streptozotocin-induced diabetic rats and by evaluation of
intestinal transport of sucrose and maltose.
2.MaterialsandMethods
2.1.ChemicalsandReagents. Streptozotocin,α-amylasefrom
Aspergillus oryzae, alpha glucosidase from Saccharomyces
cerevisiae,a n dp-Nitrophenyl α-D-glucopyranoside (PNPG)
were purchased from Sigma Chemicals, USA. All other2 Evidence-Based Complementary and Alternative Medicine
c h e m i c a l su s e df o rs t u d yw e r eo fA Rg r a d ea n dp u r c h a s e d
from Qualigens India Pvt. Ltd., Mumbai and locally.
2.2. Plant Material. Cymbopogon martinii (Roxb.) Wats was
collected from Kolhapur District, Maharashtra State, India
and identiﬁed by the Botany Department of Shivaji Uni-
versity, Kolhapur, India. The herbarium specimen has been
deposited in the Botany Department of Shivaji University
(Voucher specimen number VAG 19 for CM). The whole
plants, except roots, were air-dried in shade and grounded
into powder.
2.3. Extraction Method. To prepare a hot water extract,
100mL of water was boiled and poured on 10g of plant
powder. The preparation was closed and set aside to cool.
After cooling it was centrifuged and upper layer collected
and stored in cold condition for further use. The water
extract was subjected to diﬀerential solvent extraction with
petroleum ether, chloroform, and dichloromethane. The
alpha glucosidase inhibitory activity was detected in the
chloroform fraction. This fraction was then subjected to
silica gel column chromatography with toluene:ethyl acetate
gradient. The fractions were collected and evaluated for the
inhibitor activity. The 30:70 toluene:ethyl acetate fraction
showedoptimumactivity.10gofplantpowderyielded70mg
of the column fraction. This CM fraction was used for
further studies.
2.4. Animals. Adult male Albino rats weighing between 200
± 20g were used. The rats were fed with standard diet
purchased from Amruth, India Ltd. Animals were provided
with food and water ad libitum and maintained at 25–28◦C.
Diabetes was induced by a single intraperitoneal injection
of 70mg/kg of streptozotocin to overnight fasted rats. The
diabetic status of animals was veriﬁed after the 14th day
of injection. Animals showing blood glucose more than
150mg/dL were considered as diabetic and used in the
experiments. All experiments were carried out on group of
six animals. In vitro alpha glucosidase activity was evaluated
in quadruplet.
2.5. Eﬀect of CM Fraction on Diabetic Animals in Presence
of Disaccharides. The diabetic and normal animals (fasted
overnight for 12h.) were given an oral maltose and sucrose
load using gavage tube, and blood glucose was monitored.
2mg/g body weight of maltose and 4mg/g body weight of
sucrose were orally administered, blood was drawn from tail
tipatdeﬁnedtimeintervals,andbloodglucosewasmeasured
usingglucometer(AccucheckpurchasedfromRoche,India).
To study the eﬀect of plant extract, 5.0mg/kg body weight
of the ﬁnal column fraction was administered 5minutes
before administration of respective sugars and blood glucose
monitored. The quantity of the dose was standardized to
demonstrate optimum eﬀect.
2.6. Isolation of Alpha Glucosidase. Alpha glucosidase was
isolated as reported earlier [6]. Brieﬂy normal healthy rats
fasting for 20h were sacriﬁced by cervical dislocation. The
small intestine obtained was ﬂushed several times with ice-
cold NaCl and 50mM (pH 7.0) sodium phosphate buﬀer.
The mucosa was scraped with glass slide on ice-cold glass
surface. The obtained material was centrifuged and pellet
homogenized in phosphate buﬀer containing 1% Triton X
100; further cold butanol was added to remove Triton and
sample subjected to overnight dialysis. The enzyme thus
obtained was used after proper dilution. One unit of enzyme
activity (U) is deﬁned as amount of enzyme forming μmole
ofglucoseperminpermLunderstandardconditions. Assays
were performed in quadruplicate.
2.7. In Vitro Assay for Alpha Glucosidase and Kinetic Studies.
The activity was assayed with 1% starch, 25mM maltose,
10mM PNPG as substrate for 30min and 50mM sucrose for
an hour in presence of phosphate buﬀer pH 7.2 (100mM) at
37◦C. Reaction was stopped by heat inactivation. Released
glucose was quantiﬁed using commercial glucose oxidase
assay (GOD-PAP Biolab Diagnostics (I) PVT. LTD). The
release of PNP from PNPG was measured at 420nm. Total
inhibition for each substrate concentration was determined
and IC50 value determined at 50% inhibition. Assays were
performed in quadruplet.
Forkineticstudiesvaryingconcentrationsofmaltose(10,
15, 20, 25, and 30mM) were incubated with alpha glucosi-
dase in the absence of inhibitor and with 30 and 50μg/mL
for CM in phosphate buﬀer pH 7.2 (100mM) at 37◦C,
and amount of glucose formed was determined. Data was
presented as Lineweaver Burk plots to study the nature of
inhibition.
2.8. Inhibition Studies for Alpha Glucosidase from Yeast and
α-Amylase from Aspergillus oryzae. Alpha glucosidase (0.075
units per mL of reaction mixture) (EC 3.4.22.2) from yeast
was premixed with and without diﬀerent concentrations of
CM. 5mM PNPG was added to mixture to start the reaction.
PNP formed was measured after 30minutes of incubation
at 420nm. α-amylase (5mg per mL of reaction mixture)
was mixed with and without diﬀerent concentrations of CM,
and 1% starch as a substrate was added. Incubation was
carried out for 10min at 37◦Ca n dr e a c t i o nw a ss t o p p e db y
heat inactivation. Reducing sugar was measured by DNSA
(Dinitrosalicylic Acid) method.
3. IntestinalAbsorption Studies
Normal adult albino rats weighing about 200g were used.
After 20h of fasting, rats were sacriﬁced by cervical dislo-
cation, and the abdomen was opened by midline incision.
The whole small intestine was removed except duodenum
and lower part of ileum. The small intestine was washed
with chilled saline solution (0.9% w/v NaCl) using syringe
several times. Approximately 10cm of intestinal segments
was used for the experiment. One end of the intestinal
segment was tied and ﬁlled with 0.5mL of Henseleit bicar-
bonatebuﬀer(25mMNaHCO3,118mMNaCl,4.7mMKCl,
1.2mM MgSO4,1 . 2m MC a C l 2, and 9.7mg/L of Na2EDTA)
containing 100mM and 200mM of maltose and sucrose,Evidence-Based Complementary and Alternative Medicine 3
Table 1: Inhibition of intestinalα-glucosidase by CMwith diﬀerent
substrates. IC50 value for CM is 40μgm/mL for starch, maltose, and
PNPG, while it is 60μgm/mL for sucrose. (Acarbose shows 100%
inhibitionforallsubstrates.IC50 60μgm/mLforstarch,maltoseand
PNPG and 30μgm/mL for sucrose).
Cymbopogon martini Acarbose
Substrate IC50
(μg/mL) % inhibition IC50
(μg/mL) % inhibition
1% starch 40 98 60 100
Maltose 40 98 60 100
PNPG 40 98 60 100
S u c r o s e 6 06 83 0 1 0 0
respectively. The other end was tied, and the sac was placed
inside the organ bath containing 20mL of the same KHB
buﬀer without glucose. Temperature was maintained at
37◦C, and proper shaking was ensured. 0.1mL of 1% of
phenol red was added to the intestinal sac in all the exper-
iments to ensure that there is no leakage from the sac. The
totalincubationperiodwas40min.Theprogressofintestinal
absorption was monitored by drawing 0.1mL of the sample
for glucose measurement. Similar experiments were repeated
by addition of 0.100mg of CM and 4mg, of acarbose to the
reaction mixture.
3.1. Eﬀect of CM and Acarbose on Oral Load of Maltose and
Sucrose. Rats were fasted for 12h. 2mg/g body weight and
4mg/gbodyweightofmaltoseandsucroseloadweregivento
diabetic control rats and normal rats. The same experiment
was repeated with 5mg/kg of C. martinii and 60mg/kg of
acarbose given prior to maltose and sucrose. The level of
blood glucose was monitored at 16, 60, and 120min.
3.2. In Vivo Evaluation of Noncompetetitive Inhibiting Action
of CM. Rats were fasted for 12h. 2mg/g body weight and
3mg/g body weight of maltose load were given to diabetic
control rat. The same experiment was repeated with 5mg/Kg
of C. martinii and 60mg/Kg of acarbose given prior to
maltose load. The level of blood glucose was monitored at
16, 60, and 120min.
3.3. Data Analysis. All data were expressed as mean ± S.D.
for experiment. Statistical signiﬁcance was analyzed by one-
way analysis of variance (ANOVA) with Tukey-Kramer’s
multiple comparisons test. Readings were considered signiﬁ-
cant at P ≤ 0.05.
4. Results
4.1. Alpha Glucosidase Inhibition and Measurement of IC50
Value. It can be seen from Table 1 that CM can inhibit the
maltase activity to the tune of 98% while it is less for sucrase
activity. This is in contrast to acarbose which has 15,000
times more aﬃnity for inhibiting the sucrase activity and
can also inhibit digestion of starch and maltose [7]. Acarbose
demonstrates 100% inhibition for all the substrate.
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Figure 1: Lineweaver Burk plots for kinetic analysis of alpha
glucosidase inhibition by CM at varying concentrations of maltose
in presence and absence of diﬀerent concentrations of plant extract.
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Figure 2: % inhibition by CM ( ) and acarbose ( ) for alpha
Glucosidase from yeast and α-amylase from Aspergillus oryzae using
PNPG and starch as substrates, respectively.
5.KineticStudies
The Lineweaver Burk plot (Figure 1) for CM demonstrates a
noncompetitive to mixed type of inhibition.
5.1. Inhibition of Alpha Glucosidase from Yeast and α-Amylase
from Aspergillus oryzae. It appears that CM functions as a
broad-basedinhibitorinthatitshowedabout73%inhibition
for bacterial amylase and almost 85% inhibition of the
yeastalphaglucosidase.Acarbosehowevershowsmuchlower
inhibition (Figure 2).
5.2. In Vivo Alpha Glucosidase Inhibition Studies. The in vivo
alpha glucosidase inhibition can be demonstrated by admin-
istrationoforalmaltoseandsucroseload.Itcanbeseenfrom
Figure 3 that, as compared to diabetic control, CM shows
decrease in the level of blood glucose on maltose load. It
should be noted that although CM shows a 98% inhibition
in vitro, it demonstrates better lowering of blood glucose,
that is, 153 ± 8.6 mg/dL in 2hours as compared to acarbose.
With sucrose as the substrate (Figure 4), acarbose which has
very high aﬃnity for sucrose shows lower blood glucose
value after two hours. CM which demonstrates about 68%4 Evidence-Based Complementary and Alternative Medicine
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Figure 3:Eﬀectofmaltoseload(2mg/gofbodyweight)ondiabetic
ratsinabsenceofinhibitor( )andinpresenceofCM( ),acarbose
( ); as well as in normal rats without inhibitor ( ) with inhibitor
CM (♦), acarbose ( )( n = 6, ∗P<0.05).
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Figure 4: Eﬀect of sucrose load (4mg/g of body weight) on diabetic
ratsinabsenceofinhibitor( )andinpresenceofCM( ),acarbose
( ), as well as in normal rats without inhibitor ( )a n dw i t h
inhibitor CM (♦), acarbose ( )( n = 6, ∗P<0.05).
inhibition in vitro shows an increase by 50 ± 7.05mg/dL
as compared to acarbose. In normal animals too, a decrease
in the glucose shoot up is seen at 16min for maltose and
sucrose. Administration of CM to normal rats also showed
a lowering of postprandial glucose level as compared to the
normal rats.
5.3. Eﬀect of Plant Extracts on In Vitro Intestinal Digestion of
Disaccharides. Figure 6revealsthatCMisagoodinhibitorof
maltosetransportshowing69%inhibitionasagainstpositive
control acarbose which demonstrates a 62% inhibition.
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Figure 5: In vitro transport studies using noneverted intestinal
sacs with 200mM sucrose and measurement of glucose released in
control(whitesquare),with100μgmofCM(greysquare),and4mg
of acarbose (black square) at time intervals of 10, 20, 30, and 40
(
∗P < 0.05,
∗∗P < 0.001).
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sacs with 100mM maltose and measurement of glucose released in
control(whitesquare),with100μgmofCM(greysquare),and4mg
of acarbose (black square) at time intervals of 10, 20, 30, and 40
(
∗P < 0.05,
∗∗P < 0.001).
Acarbose is a better inhibitor of sucrase activity showing a
73% inhibition (Figure 5). In comparison CM showed 53%
inhibition.
5.4. In Vivo Noncompetitive Inhibition Study. On increasing
the maltose load from 2mg/g to 3mg/g body weight and
measuring the level of blood glucose an increase of 286 ±
12.3mg/dL and 410±10.3mg/dL,respectively ,wasobserved
after 2h in diabetic control rats (Figure 7). In case of
acarbosethoughitcanbeobservedfromFigure 8thatthe2h
bloodglucosewasreducedto250.7±11.3mg/dLwith2mg/g
body weight load of maltose as compared to diabetic control,
the level was found to increase to 375 ± 10.3mg/dL with
3mg/g body weight of maltose load. However it is important
to note that with CM the value is 128.2±9.12mg/dL at 2mg
of maltose load/g body weight which marginally increases
to 181 ± 11.4mg/dL at 3mg of maltose load/g body weight
(Figure 9) showing the noncompetitive mode of inhibition
by CM even under in vivo conditions.
6. Discussion
The use of alpha glucosidase inhibitor treatment in control
of rise in the postprandial glucose level is desirable as itEvidence-Based Complementary and Alternative Medicine 5
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Figure 7: Eﬀe c to fm a l t o s el o a do f2m g / gb o d yw e i g h t(  )a n d
3mg/g body weight ( ) in diabetic control rats.
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Figure 8:Eﬀectofmaltoseload2mg/gbodyweight( )and3mg/g
body weight ( ) in diabetic control rats in presence of 60 mg/kg
acarbose.
constitutes a noninvasive mechanism for controlling hyper-
glycemia. The STOP NIDDM study published in 2002 has
revealed the advantage of alpha glucosidase inhibitors in
prevention of progress of potential diabetic patients into
Type II diabetic patients in addition to controlling the risk of
cardiovascular damage [8]. Diabetic patients generally suﬀer
from hyperglycemic shoot up after meals which take almost
4-5hours to reduce back to the original glucose level. The
shoot up is attributed to increased disaccharidases activity
by 1.5-fold [9] and glucose transporters GLUT2 and SGLT1
activity by almost 3-4-fold in diabetic animals as compared
to normal [10]. The increased glucose level for prolonged
time leads to nonspeciﬁc glycation of proteins initiating a
cascade of secondary complications [11]. Hence, control of
postprandial glucose levels would be valuable in prevention
of secondary complications of diabetes.
Cymbopogon martinii is routinely used in the Indian
Ayurvedic Medicine System for a long period, and no known
t o x i c i t yr e p o r t sa r ea v a i l a b l en e i t h e rh a v ew eo b s e r v e da n y
toxic eﬀects in the experimental animals, even at a dose 10
times higher than reported in this paper. The plant appears
to be very good inhibitor of maltase activity while it exhibits
68% inhibition of sucrase activity. The mechanism is distinct
from acarbose which is a strong inhibitor of sucrose [12]
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Figure 9:Eﬀectofmaltoseload2mg/gbodyweight( )and3mg/g
body weight ( ) in diabetic control rats in presence of 5mg/kg of
C. martinii.( P<0.005).
(Enc et al. 2001). CM being more of a noncompetitive type
inhibitor of alpha glucosidase would bind to the enzyme at
a region other than the active site and may not be aﬀected
by higher concentration of the substrate as against acarbose
which is a competitive inhibitor [7]. We have also observed
inhibition of alpha glucosidase by Tinospora cordifolia stem
extract to be of noncompetitive type [6]. A case study on Sri
Lankan plant Cassia auriculata which has similar glucosidase
inhibitory activity shows reduction in blood glucose on
maltose load but no such action with sucrose load [8].
In case of Punica granatum the ﬂower extract is reported
to have sucrase inhibiting activity even more potent than
Salacia oblonga which is known to possess potent sucrase
inhibitionaction,howevernoactionofinhibitiononmaltose
is mentioned [13]. Acarbose shows milder inhibition of
both the alpha glucosidase from yeast and bacteria [14].
On the other hand several plant glucosidases reported to
have noncompetitive inhibition show substantial inhibition
of both these enzymes [8, 14]. The ability to bind to sites
other than the active site probably gives them a broader
speciﬁcity of inhibition as is also observed in CM.
A reduction in intestinal glucose absorption by perfusion
of glucose in rat intestine with plant extract of Plantago
ovata is suggested to be due to increased gastric motility
by the high ﬁber content and not due to inhibition of the
transporter [15]. To ensure that reduction in blood glucose
was due to inhibition of alpha glucosidase activity, in vitro
intestinal absorption was studied. CM appears to be a better
inhibitor of maltase activity than acarbose although the
latter has higher sucrase inhibiting action. However, as the
regular diet is rich in starch than sucrose, CM apparently has
better advantage in treatment of diabetes. Unlike acarbose
which is reported to stimulate GLP-1 secretion leading to
insulin release and helping in reduction in postprandial
glucose level [12] no increase in insulin level was evident
with CM revealing that their antihyperglycemic action is
predominantlyduetoinhibitionofalphaglucosidase(results
not shown). It is interesting to note that although acarbose
demonstrates better IC50 value and 1000% inhibition of
maltose activity in vitro CM shows better inhibition in vivo
and presents shoot up in blood glucose value for prolonged6 Evidence-Based Complementary and Alternative Medicine
periodwhichisadvantagesintreatmentofdiabetes.Itshould
also be noted from Figures 3 and 4 that inhibitory action of
CM is at a concentration of 5.0mg/kg body weight as against
60mg/kg body weight for acarbose. On further puriﬁcation
of the active principle the required inhibitory concentration
of the plant components will be even lower, demonstrating
their potent alpha glucosidase inhibitory action.
The major advantage of CM over acarbose, apart from
its higher maltase inhibitory action, is that it demonstrates
noncompetitive mode of inhibition. It is evident that, with
higher feed, higher concentration of acarbose would be
needed to show the same eﬀect; the same is not the case
with CM which is still eﬀective at lower concentration. The
major side eﬀects of acarbose such as ﬂatulence, intestinal
disturbances would be enhanced with higher concentration.
In conclusion we report for the ﬁrst time, Cymbopogon
martiniicommonlyfoundgrasseverywherewithnoreported
toxicity to possess excellent alpha glucosidase inhibition
activity. The eﬀect is more pronounced for CM as compared
to acarbose which is currently the most widely used alpha
glucosidase inhibitor for treatment of diabetes. Thus CM can
generate better lead molecule as alpha glucosidase inhibitor
for treatment of diabetes mellitus particularly in control of
postprandial glucose level.
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